Analyst RecommendationAnalyst reiterates BUY recommendation, believing shares remain undervalued ahead of internal/external catalysts.
Financial PerformanceVoyager has $295M in cash and a projected runway into mid-2027, indicating meaningful potential value creation from clinical advancement, partnering activity, and platform validation.
Gene Therapy DevelopmentVoyager disclosed a new APOE-targeted IV gene therapy that leverages the company’s proprietary BBB-penetrant TRACER capsid platform for the delivery of a bifunctional payload.